Royalty Pharma plc Class A Ordinary Shares

RPRXNASDAQ • USD
ThemeAsset Mgmt & Capital Mkts›Private Equity & Alternative Investments
49.38 USD
↘ 0.26 (0.52%)AT CLOSE (11:59 AM EDT)
49.20
↘ 0.18 (0.37%)
POST MARKET (AS OF 07:54 PM EDT)
Post Market
AS OF 07:54 PM EDT
49.20
↘ 0.18 (0.37%)
🔴Market: CLOSED
Open?$49.64
High?$49.91
Low?$49.20
Prev. Close?$49.64
Volume?2.0M
Avg. Volume?3.0M
VWAP?$49.56
Rel. Volume?0.65x
Bid / Ask
Bid?$46.76 × 100
Ask?$52.40 × 100
Spread?$5.64
Midpoint?$49.58
Valuation & Ratios
Market Cap?21.9B
Shares Out?444.4M
Float?406.4M
Float %?94.9%
P/E Ratio?28.46
P/B Ratio?3.39
EPS?$1.73
Dividend?3.34%
Ex-Dividend?2026-05-15
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?2.40Strong
Quick Ratio?2.40Strong
Cash Ratio?0.97Adequate
Debt/Equity?1.40Moderate
ValuationRICHLY VALUED
Score
47/100
P/E?
28.5FAIR▾
P/B?
3.39FAIR▾
P/S?
9.23HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
21.0HIGH▾
EV/Sales?
12.78HIGH▾
Returns & Efficiency
ROE?
11.9%FAIR▾
ROA?
3.9%FAIR▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$30.4B
Fundamentals ratios updated end of day
xxx
Related Companies
Loading...
News
Profile
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Employees
100
Market Cap
21.9B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.royaltypharma.com
Listed
2020-06-16
Address
110 EAST 59TH STREET
NEW YORK, NY 10022
Phone: (212) 883-0200
MarketsMoversWatchlist